Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) is now available.
Ab&B Bio-Tech CO., LTD. JS, a Chinese vaccine company specializing in innovative and premium vaccines such as quadrivalent and trivalent subunit influenza candidates and a lyophilized human rabies vaccine candidate, is positioning itself to substitute traditional and imported vaccines domestically and build a broader global footprint. The company announced that its H shares will be included in the Hang Seng Composite Index from March 9, 2026, a move the board views as recognition of its business performance and growth prospects, expected to broaden its shareholder base, boost liquidity in its H shares, and strengthen its market reputation and brand visibility.
The Hang Seng Composite Index covers about 95% of the market capitalization on the HKEX Main Board and serves as a key benchmark for index and mutual funds as well as performance evaluation systems. Ab&B Bio-Tech’s inclusion may increase institutional interest and passive fund tracking of its shares, potentially enhancing its standing in the capital markets and supporting future capital-raising and expansion efforts.
The most recent analyst rating on (HK:2627) stock is a Sell with a HK$47.00 price target. To see the full list of analyst forecasts on Ab&B Bio-Tech CO., LTD. JS Class H stock, see the HK:2627 Stock Forecast page.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine developer and manufacturer focused on innovative and upgraded traditional vaccines. The company tracks global infectious disease trends and vaccine R&D, with a strategic emphasis on premium vaccines aimed at replacing traditional and imported products in China while expanding into international markets.
Average Trading Volume: 226,102
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$20.26B
See more insights into 2627 stock on TipRanks’ Stock Analysis page.